ACC 2022 The long-term follow-up of the SPYRAL HTN-ON MED trial showed that radiofrequency renal denervation is associated with clinically meaningful BP reductions up to 36 months, without safety issues, in patients with uncontrolled hypertension on antihypertensive medications.

ACC 2022 An analysis showed that transcatheter aortic valves were less likely to have hemodynamic valve deterioration over a 5-year period compared to surgical valves. “This is potentially practice changing” said Coylewright.

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

ACC 2022 A post hoc pooled analysis from the ORION-10 and ORION-11 trials showed that inclisiran, compared with placebo, in addition to statin and/or ezetimibe provided effective and sustained LDL-c lowering in patients with prior MI.

ACC 2022 Megan Coylewright gives her view on the results of the ADAPT-TAVR trial which investigated whether edoxaban, compared to DAPT can reduce leaflet thrombosis, cerebral thromboembolism and neurological/neurocognitive dysfunction after TAVR.

ACC 2022 Prof. Handberg shares and interprets the findings from the SuperWIN study. "We have the ability with this type of intervention to really impact multiple generations", she said.

ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

ACC 2022 A randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

ACC 2022 Does sodium thiosulfate reduces infarct size in patients after STEMI? Marie-Sophie de Koning presents the findings of the GIPS-IV trial.

ACC 2022 There was no reduction in infarct size after 4 months in STEMI patients treated with sodium thiosulfate compared with patients in the placebo group, in the GIPS-IV trial.

ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.

ACC 2022 Florian Rader presents interim results of MAVA-LTE, a long-term extension study of EXPLORER-HCM with mavacamten in hypertrophic cardiomyopathy (HCM).